Literature DB >> 17488974

GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue.

Kristoffer L Egerod1, Birgitte Holst, Pia S Petersen, Jacob B Hansen, Jan Mulder, Tomas Hökfelt, Thue W Schwartz.   

Abstract

G protein-coupled receptor 39 (GPR39) is a constitutively active, orphan member of the ghrelin receptor family that is activated by zinc ions. GPR39 is here described to be expressed in a full-length, biologically active seven-transmembrane form, GPR39-1a, as well as in a truncated splice variant five-transmembrane form, GPR39-1b. The 3' exon of the GPR39 gene overlaps with an antisense gene called LYPD1 (Ly-6/PLAUR domain containing 1). Quantitative RT-PCR analysis demonstrated that GPR39-1a is expressed selectively throughout the gastrointestinal tract, including the liver and pancreas as well as in the kidney and adipose tissue, whereas the truncated GPR39-1b form has a more broad expression pattern, including the central nervous system but with highest expression in the stomach and small intestine. In contrast, the LYPD1 antisense gene is highly expressed throughout the central nervous system as characterized with both quantitative RT-PCR and in situ hybridization analysis. A functional analysis of the GPR39 promoter region identified sites for the hepatocyte nuclear factors 1alpha and 4alpha (HNF-1alpha and -4alpha) and specificity protein 1 (SP1) transcription factors as being important for the expression of GPR39. In vivo experiments in rats demonstrated that GPR39 is up-regulated in adipose tissue during fasting and in response to streptozotocin treatment, although its expression is kept constant in the liver from the same animals. GPR39-1a was expressed in white but not brown adipose tissue and was down-regulated during adipocyte differentiation of fibroblasts. It is concluded that the transcriptional control mechanism, the tissue expression pattern, and in vivo response to physiological stimuli all indicate that the GPR39 receptor very likely is of importance for the function of a number of metabolic organs, including the liver, gastrointestinal tract, pancreas, and adipose tissue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488974     DOI: 10.1210/me.2007-0055

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  22 in total

Review 1.  GPR39: a Zn(2+)-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions.

Authors:  Petra Popovics; Alan J Stewart
Journal:  Cell Mol Life Sci       Date:  2010-09-02       Impact factor: 9.261

2.  Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists.

Authors:  Stefan Peukert; Richard Hughes; Jill Nunez; Guo He; Zhao Yan; Rishi Jain; Luis Llamas; Sarah Luchansky; Adam Carlson; Guiqing Liang; Vidya Kunjathoor; Mike Pietropaolo; Jeffrey Shapiro; Anja Castellana; Xiaoping Wu; Avirup Bose
Journal:  ACS Med Chem Lett       Date:  2014-08-04       Impact factor: 4.345

3.  Protective Effects of Co-administration of Zinc and Selenium Against Streptozotocin-Induced Alzheimer's Disease: Behavioral, Mitochondrial Oxidative Stress, and GPR39 Expression Alterations in Rats.

Authors:  Yaghoob Farbood; Alireza Sarkaki; Masoud Mahdavinia; Ata Ghadiri; Ali Teimoori; Faezeh Seif; Mohammad Amin Dehghani; Seyedeh Parisa Navabi
Journal:  Neurotox Res       Date:  2020-06-05       Impact factor: 3.911

4.  Control of coronary vascular resistance by eicosanoids via a novel GPCR.

Authors:  Nabil J Alkayed; Zhiping Cao; Zu Yuan Qian; Shanthi Nagarajan; Xuehong Liu; Jonathan W Nelson; Fuchun Xie; Bingbing Li; Wei Fan; Lijuan Liu; Marjorie R Grafe; Catherine M Davis; Xiangshu Xiao; Anthony P Barnes; Sanjiv Kaul
Journal:  Am J Physiol Cell Physiol       Date:  2022-04-06       Impact factor: 5.282

5.  G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction.

Authors:  Birgitte Holst; Kristoffer L Egerod; Chunyu Jin; Pia Steen Petersen; Mette Viberg Østergaard; Jacob Hald; A M Ejernaes Sprinkel; Joachim Størling; Thomas Mandrup-Poulsen; Jens J Holst; Peter Thams; Cathrine Orskov; Nils Wierup; Frank Sundler; Ole D Madsen; Thue W Schwartz
Journal:  Endocrinology       Date:  2009-02-12       Impact factor: 4.736

6.  Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39.

Authors:  Jian V Zhang; Holger Jahr; Chin-Wei Luo; Cynthia Klein; Kristof Van Kolen; Luc Ver Donck; Ananya De; Esther Baart; Jing Li; Dieder Moechars; Aaron J W Hsueh
Journal:  Mol Endocrinol       Date:  2008-03-12

7.  Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC-derived mutant β cells.

Authors:  Chang Siang Lim; Shirley Suet Lee Ding; Yaw Sing Tan; Blaise Su Jun Low; Natasha Hui Jin Ng; Vidhya Gomathi Krishnan; Su Fen Ang; Claire Wen Ying Neo; Chandra S Verma; Shawn Hoon; Su Chi Lim; E Shyong Tai; Adrian Kee Keong Teo
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

8.  The hungry stomach: physiology, disease, and drug development opportunities.

Authors:  Gareth J Sanger; Per M Hellström; Erik Näslund
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

9.  β-Cell Specific Overexpression of GPR39 Protects against Streptozotocin-Induced Hyperglycemia.

Authors:  Kristoffer L Egerod; Chunyu Jin; Pia Steen Petersen; Nils Wierup; Frank Sundler; Birgitte Holst; Thue W Schwartz
Journal:  Int J Endocrinol       Date:  2011-11-17       Impact factor: 3.257

Review 10.  Role of GPR39 in Neurovascular Homeostasis and Disease.

Authors:  Yifan Xu; Anthony P Barnes; Nabil J Alkayed
Journal:  Int J Mol Sci       Date:  2021-07-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.